{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Lindstrom LS"],"funding":["FORTE","Swedish Cancer Society","Stockholm Cancer Society","NCI NIH HHS","Swedish Research Council"],"pagination":["726-733"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6037086"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["110(7)"],"pubmed_abstract":["Background
Breast cancer patients with estrogen receptor (ER)-positive disease have a continuous long-term risk for fatal breast cancer, but the biological factors influencing this risk are unknown. We aimed to determine whether high intratumor heterogeneity of ER predicts an increased long-term risk (25 years) of fatal breast cancer.Methods
The STO-3 trial enrolled 1780 postmenopausal lymph node-negative breast cancer patients randomly assigned to receive adjuvant tamoxifen vs not. The fraction of cancer cells for each ER intensity level was scored by breast cancer pathologists, and intratumor heterogeneity of ER was calculated using Rao's quadratic entropy and categorized into high and low heterogeneity using a predefined cutoff at the second tertile (67%). Long-term brea"],"journal":["Journal of the National Cancer Institute"],"pubmed_title":["Intratumor Heterogeneity of the Estrogen Receptor and the Long-term Risk of Fatal Breast Cancer."],"pmcid":["PMC6037086"],"funding_grant_id":["2014-2271","2016-00081","2014-1962","P30 CA016086","521-2014-2057","CAN2016/684"],"pubmed_authors":["Datnow B","Yau C","Czene K","Hasteh F","Bishop JW","Carpenter PM","Thompson CK","Hoadley KA","Borowsky AD","Chen YY","Stal O","Benz CC","Lindstrom LS","Fornander T","Esserman LJ","Balassanian R","Krings G","STO Trialists Group","Zhang Y","Van't Veer LJ","Lin F","Nordenskjold B"],"additional_accession":[]},"is_claimable":false,"name":"Intratumor Heterogeneity of the Estrogen Receptor and the Long-term Risk of Fatal Breast Cancer.","description":"Background
Breast cancer patients with estrogen receptor (ER)-positive disease have a continuous long-term risk for fatal breast cancer, but the biological factors influencing this risk are unknown. We aimed to determine whether high intratumor heterogeneity of ER predicts an increased long-term risk (25 years) of fatal breast cancer.Methods
The STO-3 trial enrolled 1780 postmenopausal lymph node-negative breast cancer patients randomly assigned to receive adjuvant tamoxifen vs not. The fraction of cancer cells for each ER intensity level was scored by breast cancer pathologists, and intratumor heterogeneity of ER was calculated using Rao's quadratic entropy and categorized into high and low heterogeneity using a predefined cutoff at the second tertile (67%). Long-term brea","dates":{"release":"2018-01-01T00:00:00Z","publication":"2018 Jul","modification":"2025-04-21T19:27:02.824Z","creation":"2019-03-26T23:46:01Z"},"accession":"S-EPMC6037086","cross_references":{"pubmed":["29361175"],"doi":["10.1093/jnci/djx270"]}}